Prophylactic and interventional granulocyte transfusions in patients with haematological malignancies and life-threatening infections during neutropenia

Annals of Hematology

Volumn 84, Issue 11, 2005, Pages 734-741

  Mousset, Sabine ^a   Hermann, Stella ^a   Klein, Stefan A ^a   Bialleck, Heike ^a   Duchscherer, Michaele ^a   Bomke, Barbara ^a   Wassmann, Barbara ^a   Böhme, Angelika ^a   Hoelzer, Dieter ^a   Martin, Hans ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Cellular therapies; Fungal infection; Granulocyte transfusion; Neutropenia; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GRANULOCYTE TRANSFUSION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT INFECTION; SAFETY; SECONDARY PREVENTION; SURVIVAL RATE; SURVIVAL TIME; TREATMENT CONTRAINDICATION;

ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; BLOOD TRANSFUSION; FEMALE; GRANULOCYTES; HEMATOLOGIC NEOPLASMS; HUMANS; INTENSIVE CARE; LEUKEMIA; LEUKOCYTE TRANSFUSION; LIVING DONORS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA;

EID: 26844453380     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-005-1055-z     Document Type: Article

References (27)

1. Adkins DR, Goodnough LT, Moellering J, Brown R, Khoury H, Vij R, DiPersio J (1999) Reduction in antibiotic utilization and of febrile days by transfusion of G-CSF mobilized prophylactic granulocyte components: A randomised study. Blood 94:590a
2. Adkins DR, Goodnough LT, Shenoy S, Brown R, Moellering J, Khoury H, Vij R, DiPersio J (2000) Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation. Blood 95:3605-3612
3. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE, Erjavec Z, Fiere D, Lortholary O, Maertens J, Meis JF, Patterson TF, Ritter J, Selleslag D, Shah PM, Stevens DA, Walsh TJ (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and haematopoietic stem cell transplants: An international consensus. Clin Infect Dis 34:7-14
4. Bensinger WI, Price TH, Dale DC, Appelbaum FR, Clift R, Lilleby K, Williams B, Storb R, Thomas ED, Buckner CD (1993) The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood 81:1883-1888
5. Blum W, Hallem C, Vij R, Shenoy S, Goodnough L, Brown R, Khoury H, Westervelt P, DiPersio J, Adkins D (2001) Improved survival in allogeneic peripheral blood stem cell (PBSC) transplant recipients who received prophylactic granulocyte transfusions from HLA-matched donors: long-term follow-up. Blood 98:58a
6. Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340
7. Bux J, Dielschneider T, Duscherer M, Edel E, Eichler H, Haas C, Moog R, Peschke H, Peters C, Ryzenkov I, Schlenke P, Ullrich H, Wiesneth M (2003) Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: Results of a multicentre study. Vox Sang 85:322-325
8. Caspar CB, Seger RA, Burger J, Gmür J (1993) Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood 81:2866-2871
9. Cordonnier C, Maury S, Pautas C, Bastié J.N. Chehata S. Castaigne S. Kuentz M. Bretagne S. Ribaud P. 2004 Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients Bone Marrow Transplant 33 943-948
10. Denning DW (1998) Invasive aspergillosis. Clin Infect Dis 26:781-803
11. Dignani MC, Anaissie EJ, Hester JP, O'Brien S, Vartivarian SE, Rex JH, Kantarjian H, Jendiroba DB, Lichtiger B, Nadersson BS, Freireich EJ (1997) Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia 11:1621-1630
12. Freireich EJ, Levin RH, Whang J, Carbone PP, Bronson W, Morse EE (1964) The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic patients. Ann NY Acad Sci 113:1081-1090 1:STN:280:CCuD2sfisVY%3D
13. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene R, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HAT, Troke PF, De Pauw B (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347:408-415
14. Hermann S, Klein SA, Jacobi V, Thalhammer A, Bialleck H, Duchscherer M, Wassmann B, Hoelzer D, Martin H (2001) Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol 113:446-454
15. Häbel K, Carter RA, Liles WC, Dale DC, Price TH, Bowden RA, Rowley RD, Chauncey TR, Bensinger WI, Boeckh M (2002) Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: A comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion 42:1414-1421
16. Illerhaus G, Wirth A, Dwenger A, Waller CF, Garbe A, Brass V, Lang H, Lange W (2002) Treatment and prophylaxis of severe infections in neutropenic patients by granulocyte transfusions. Ann Hematol 81:273-281
17. Kerr JP, Liakopolou E, Brown J, Cornish JM, Fleming D, Massey E, Oakhill A, Pamphilon DH, Robinson SP, Totem A, Valencia AMP, Marks DI (2003) The use of stimulated granulocyte transfusions to prevent recurrence of past severe infections after allogenic stem cell transplantation. Br J Haematol 123:114-118
18. Klein SA, Hermann S, Dietrich CF, Hoelzer D, Martin H (2002) Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188-labeled anti-CD66 monoclonal antibody. Blood 99:2270-2271
19. Lee JJ, Chung IJ, Park MR, Kook H, Hwang TJ, Ryang DW, Kim HJ (2001) Clinical efficacy of granulocyte transfusion therapy in patients with neutropenia-related infections. Leukemia 15:203-207
20. Offner F, Cordonnier C, Ljungmann P, Prentice HG, Engelhard D, De Bacquer D, Meunier F, De Pauw B (1998) Impact of previous aspergillosis on the outcome of bone marrow transplantation. Clin Infect Dis 26:1098-1103
21. Peters C, Minkov M, Matthes-Martin S, Pötschger U, Witt V, Mann G, Höcker P, Worel N, Stary J, Klingebiel T, Gadner H (1999) Leucocyte transfusions from rhG-CSF or prednisolone stimulated donors for treatment of severe infections in immunocompromised patients. Br J Haematol 106:689-696
22. Price TH, Raleigh AB, Boeckh M, Bux J, Nelson K, Liles C, Dale DC (2000) Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood 95:3302-3309
23. Robinson SP, Marks DI (2004) Granulocyte transfusions in the G-CSF era. Where do we stand? Bone Marrow Transplant 34:839-846
24. Rutella S, Pierelli L, Piccirillo N, Sica S, Serafini R, Chiusolo P, Paladini U, Leone F, Zini G, D'Onofrio G, Leone G (2003) Efficacy of granulocyte transfusions for neutropenia-related infections: retrospective analysis of predictive factors. Cytotherapy 5:19-30
25. Strauss RG (1995) Clinical perspectives of granulocyte transfusions: efficacy to date. J Clin Apher 10:114-118
26. Vamvakas EC, Pineda AA (1996) Meta-analysis of clinical studies of the efficacy of granulocyte transfusions in the treatment of bacterial sepsis. J Clin Apher 11:1-9
27. Vij R, DiPersio JF, Venkatraman P, Trinkaus K, Goddnough LT, Brown RA, Khoury HJ, Devine SM, Oza A, Shenoy S, Blum W, Adkins D (2003) Donor CMV serostatus has no impact on CMV viremia or disease when prophylactic granulocyte transfusions are given following allogenic peripheral blood stem cell transplantation. Blood 101:2067-2069